Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...
The C-POST study involved 415 patients who were randomized to receive either Libtayo or a placebo for up to 48 weeks ... The company plans to submit a supplementary biologics license application for ...
Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback